The advent of next-generation androgen receptor pathway inhibitors (ARPIs), including abiraterone and enzalutamide (ENZA), has further improved outcomes for patients with castration-resistant PCa (CRPC). This evidence concerns the gene AR and posterior cortical atrophy.